Brolucizumab ─ termination of 4 weekly trials ─ rebalancing the immunogenicity risk.
Ashish SharmaNilesh KumarNikulaa ParachuriJean-Yves SahyounBaruch D KuppermannFrancesco Maria BandelloPublished in: Expert opinion on biological therapy (2022)
Keyphrases